

# Curriculum Vitae

Last Updated: 12/1/2023

## **PERSONAL DATA**

Name: David R. Shprecher, FAAN, D.O., M.S.C.I  
Citizenship: United States

## **EDUCATION**

<b><u>Years</u></b>	<b><u>Degree</u></b>	<b><u>Institution (Area of Study)</u></b>
2007 - 2009	Fellow	University of Rochester (Movement Disorders) Rochester, NY
2007 - 2011	M.S.	University of Rochester (Clinical Investigation) Rochester, NY
2004 - 2007	Resident	University of Utah School of Medicine (Neurology) Salt Lake City, UT
2003 - 2004	Intern	University of Utah School of Medicine (Internal Medicine) Salt Lake City, UT
1999 - 2003	D.O.	Lake Erie College of Osteopathic Medicine (Osteopathic Medicine) Erie, PA
1991 - 1995	B.S.	Cornell University College of Arts and Sciences (Biology) Ithaca, NY

## **BOARD CERTIFICATIONS**

05/11/2008 - Present      American Board of Psychiatry & Neurology (Neurology), Certified

## **CURRENT LICENSES/CERTIFICATIONS**

2009 – Present      State License (UT) - Osteopathic Physician (DO)  
2015 - Present      State License (AZ) - Osteopathic Physician (DO)

## **ACADEMIC HISTORY**

### **University of Utah Department of Neurology: 07/01/2009 – Present**

07/01/2009      New Hire, Tenure Track , Assistant Professor  
02/06/2016      Adjunct Assistant Professor  
03/01/2017      Adjunct Associate Professor

### **University of Arizona College of Medicine-Phoenix Department of Neurology: 9/21/2016-Present**

09/21/2016      Appointment, non-Tenure Track, Clinical  
Associate Professor

## **PROFESSIONAL EXPERIENCE**

### **Full-Time Positions**

2015 - Present	Movement Disorders Director, Banner Sun Health Research Institute, Sun City, AZ
2009 - 2016	Assistant Professor, University of Utah, Salt Lake City, UT
2008	Attending Physician, Rochester General Hospital, Rochester, NY
2007 - 2009	Instructor, University of Rochester, Rochester, NY
1999	Personal Trainer, Equinox, New York, NY
1995 - 1998	Patient Care Technician, Beth Israel Medical Center, New York, NY

### **PROFESSIONAL EXPERIENCE**

#### **Full-Time Positions**

2015 - Present	Movement Disorders Director, Banner Sun Health Research Institute, Sun City, AZ
2009 - 2016	Assistant Professor, University of Utah, Salt Lake City, UT
2008	Attending Physician, Rochester General Hospital, Rochester, NY
2007 - 2009	Instructor, University of Rochester, Rochester, NY
1999	Personal Trainer, Equinox, New York, NY
1995 - 1998	Patient Care Technician, Beth Israel Medical Center, New York, NY

#### **Reviewer Experience**

Reviewer for Sleep  
Reviewer for Journal of Parkinson disease  
Reviewer for Journal of Alzheimer Disease  
Reviewer for Neurobiology of Aging  
Reviewer for Frontiers in Neurology  
Reviewer for Brain Sciences  
Reviewer for F1000  
Reviewer for JAMA Neurology  
Reviewer for PLOS ONE  
Reviewer for BioMedCentral Neurology  
Reviewer for Journal of the American Geriatrics Society  
Reviewer for Tremor and Other Hyperkinetic Disorders  
Reviewer for Movement Disorders Clinical Practice  
Reviewer for European Journal of Neurology  
Reviewer for Clinical Neurology and Neurosurgery  
Reviewer for Journal of the Neurological Sciences  
Reviewer for Parkinsonism and Related Disorders

## **SCHOLASTIC HONORS**

2022	Department Chairman's Award for Resident Teaching, Banner University Medical Center/University of Arizona-Phoenix
2020	Fellow, FAAN
2017	Honoree, 2017 Celebration of Hope Gala, Huntington's Disease Society of America, Arizona Chapter
2014	Vitae 2014: People and stories that drive research, University of Utah
2014 - 2015	Huntington Disease Society of America Utah Affiliate Service Award
2008 - 2010	NIH Clinical Research Loan Repayment Program
2007 - 2009	NIH Training Grant T32 NS 07338-11 Principal Investigator: Robert Griggs, MD
2007	Neurology Resident Teaching Award, University of Utah
2003	Psi Sigma Alpha, Lake Erie College of Osteopathic Medicine

## **ADMINISTRATIVE EXPERIENCE**

### **Administrative Duties**

2019 - Present	Co-Director Tourette Association of America Center of Excellence Arizona Program
2015 - Present	Movement Disorders Director, Banner Sun Health Research Institute
2015 - 2016	Co-Director, Tourette Association of America Center of Excellence at the University of Utah
2011 - 2015	Chief, Sleep & Movement Disorders Division, University of Utah Department of Neurology

### **Professional Organization & Scientific Activities**

2019 - Present	Chair/Co-Chair, Parkinson Study Group, Non-motor symptoms working group
----------------	---

### **Grant Review Committee/Study Section**

2017 - Present	Grant Review Committee Member, Lewy Body Dementia Association, Lilburn, GA
2016 - Present	Grant Review Committee Member, Weston Brain Institute, Toronto, Ontario, Canada

### **Symposium/Meeting Chair/Coordinator**

2020 - Present	Event Co-Chair. Alzheimer's, Lewy body and Related Dementias; Banner Sun Health Research Institute; Sun City, AZ
2014 - 2015	Event Organizer and lecturer, Annual Tourette Syndrome Education Symposium, University of Utah, Salt Lake City, UT
2011 - 2015	Event Organizer and lecturer, Annual Huntington Disease Education Symposium, University of Utah, Salt Lake City, UT
2010 - 2013	Monthly workshop organizer, Neuropsychiatric Movement and Associated Disorders working group, University of Utah Brain Institute.

## **UNIVERSITY COMMUNITY ACTIVITIES**

### **University of Utah Health**

2012 - 2015                      Member & Representative, Risk Management Committee, member and representative for Neurology

### **Department Level**

2011 - 2015                      Member, Neurology, Resident Selection Committee

2005 - 2015                      Member, Neurology, Resident Education Committee

## **CURRENT MEMBERSHIPS IN PROFESSIONAL SOCIETIES**

American Academy of Neurology

American Medical Association

Huntington Study Group

Movement Disorder Society

Parkinson Study Group

## **FUNDING**

### **Active Grants**

07/20/21 - Present                      Blinded Comparison of Different Alpha-Synuclein Seeding Assays as Cutaneous Biomarkers of Lewy Body Dementias  
Role: Local Site Investigator

### **Past Grants**

07/01/21 - 06/30/22                      Establishing a network for prodromal synucleinopathy research in Arizona  
Principal Investigator(s): David R. Shprecher

Role: Principal Investigator

07/01/17 - 06/30/18                      Autopsy-Based Feasibility: Clinically Separating AD Subjects Based on Underlying Lewy Body Disease

Principal Investigator(s): David R. Shprecher; Thomas Beach

Arizona Alzheimer's Consortium

Role: Principal Investigator

07/01/16 - 06/30/21                      Population Survey and Clinicopathological Study Initiation for Idiopathic REM Sleep Behavior Disorder in Sun City, Arizona

Principal Investigator(s): David R. Shprecher

Arizona Alzheimer's Consortium

Role: Principal Investigator

07/01/10 - 01/01/13                      Colonoscopic screening for autonomic pathology in Parkinson disease and dementia with Lewy bodies

Principal Investigator(s): David R. Shprecher

University of Utah Research Foundation Seed Grant

Role: Principal Investigator

01/25/10 - 01/01/13                      Neuroimaging to elucidate the mechanism of tic resolution in Tourette syndrome

Principal Investigator(s): David R. Shprecher  
University of Utah Department of Radiology  
Role: Principal Investigator

**Active Contracts**

- 07/11/22 - Present      A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared with Placebo in Participants With Early PD  
Annovis  
Role: Site Principal Investigator
- 09/05/22 - Present      Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early Stage Parkinson's Disease in Participants Between the Ages of 30 and 80 LUMA  
Biogen/Denali Therapeutics Inc  
Role: Site Principal Investigator
- 08/03/22 - Present      Study to Evaluate the Safety and Efficacy of JZP385 in the Treatment of Adults with Moderate to Severe Essential tremor  
Jazz Pharmaceuticals  
Role: Site Principal Investigator
- 07/11/22 - Present      Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies (COG1201)  
Cognition Therapeutics  
Role: Site Principal Investigator
- 05/03/21 - Present      A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease  
Principal Investigator(s): David R. Shprecher  
Neuraly  
Role: Site Principal Investigator
- 04/05/21 - Present      A Validation Study to Assess the Validity, Measurement Responsiveness, & Reliability of the Parkinson's Disease Functional Impacts Digital Instrument (PD-FIDI) in Patients with Parkinson's Disease (PD) with or without Glucocerebrosidase (GBA) Mutations  
Sanofi-Aventis  
Role: Site Principal Investigator
- 09/01/20 - Present      Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease  
AbbVie Inc.  
Role: Site Sub-Investigator
- 06/01/20 - Present      Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease  
AbbVie Inc.  
Role: Site Sub-Investigator
- 01/01/16 - Present      Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression (PPMI)  
Michael J. Fox Foundation for Parkinson's Research  
Role: Site Principal Investigator

## Past Contracts

02/01/22 – 12/20/22	A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease (PADOVA) Role: <u>Primary Site Investigator</u>
04/26/21 - 07/11/22	A Study of E2027 in Participants With Dementia With Lewy Bodies or Parkinson's Disease Dementia With or Without Amyloid Co-pathology Eisai, Inc. Role: <u>Site Principal Investigator</u>
03/01/20 - 03/01/21	North American Prodromal Synucleinopathy Consortium (NAPS) Principal Investigator(s): Yo-el Ju National Institutes of Health Role: <u>Site Principal Investigator</u>
06/03/19 - 12/31/20	Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Participants With Dementia With Lewy Bodies Eisai, Inc. Role: <u>Site Principal Investigator</u>
04/01/19 - 09/01/21	Clinical Effect of Ampreloxetine (TD-9855) for Treating symptomatic neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure Theravance Role: <u>Site Principal Investigator</u>
03/01/19 - 11/30/19	Orally Administered ENT-01 for Parkinson's Disease-Related Constipation (KARMET) Enterin Inc. Role: <u>Site Principal Investigator</u>
12/01/18 - 06/01/21	The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study ACADIA Pharmaceuticals Inc. Role: <u>Site Investigator</u>
12/01/18 - 10/01/19	Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome Neurocrine Biosciences, Inc. Role: <u>Site Principal Investigator</u>
05/01/18 - 10/02/19	Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome Neurocrine Biosciences, Inc. Role: <u>Site Principal Investigator</u>
02/16/18 - 12/31/20	Effect of LY3154207 on Cognition in Mild-to-Moderate Parkinson's Disease Dementia Eli Lilly and Company Role: <u>Site Principal Investigator</u>
02/08/18 - 06/01/20	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, with an Active-Treatment Dose-Blinded Period, to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects with Parkinson's Disease Biogen Idec Inc Role: <u>Site Principal Investigator</u>

02/03/18 - 04/30/19	<p>An Open-Label Study in Subjects with Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 for up to 4 Weeks in an Outpatient Environment</p> <p>AbbVie Inc.</p> <p>Role: <u>Site Principal Investigator</u></p>
01/30/18 - 08/31/18	<p>A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Tourette Syndrome</p> <p>Neurocrine Biosciences, Inc.</p> <p>Role: <u>Site Principal Investigator</u></p>
09/01/17 - 03/30/20	<p>Phase II Study of BMS-986168 in Patients With Progressive Supranuclear Palsy (PASSPORT)</p> <p>Biogen Idec Inc</p> <p>Role: <u>Site Principal Investigator</u></p>
06/01/17 - 06/01/18	<p>Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)</p> <p>Axovant Sciences Ltd.</p> <p>Role: <u>Site Principal Investigator</u></p>
01/01/17 - 12/01/17	<p>Phase III Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's Patients Using Levodopa (TOZ-PD)</p> <p>Biotie Therapies</p> <p>Role: <u>Site Principal Investigator</u></p>
09/01/16 - 12/01/17	<p>SYN120 a Dual 5-HT<sub>6</sub>/5-HT<sub>2A</sub> Antagonist Proof of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)</p> <p>Biotie Therapies</p> <p>Role: <u>Site Principal Investigator</u></p>
08/01/16 - 01/31/18	<p>Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study</p> <p>Axovant Sciences Ltd.</p> <p>Role: <u>Site Principal Investigator</u></p>
06/01/16 - 06/01/19	<p>Study of Urate Elevation in Parkinson's Disease, Phase 3 (SURE-PD3)</p> <p>National Institute of Neurological Disorders and Stroke</p> <p>Role: <u>Site Principal Investigator</u></p>
06/01/16 - 09/30/17	<p>A randomized, double-blind, placebo-controlled study to assess the safety and efficacy of NBI-98854 in children and adolescents with Tourette syndrome</p> <p>Neurocrine Biosciences, Inc.</p> <p>Role: <u>Site Principal Investigator</u></p>
06/01/16 - 09/30/17	<p>A randomized, double-blind, placebo-controlled study to assess the safety and efficacy of NBI-98854 in adults with Tourette syndrome</p> <p>Neurocrine Biosciences, Inc.</p> <p>Role: <u>Site Principal Investigator</u></p>
01/01/16 - 04/30/17	<p>A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease</p> <p>Kyowa Hakko Bio Co., Ltd.</p>

01/01/16 - 12/31/16	<p>Role: <u>Site sub-Investigator</u></p> <p>Open-Label Safety Study of ADS-5102 in PD Patients With levodopa induced dyskinesia          Adamas Pharmaceuticals, Inc.          Role: <u>Site sub-Investigator</u></p>
07/01/15 - 03/31/17	<p>Efficacy and Safety Study of MYOBLOC® Followed by Open-Label Multiple-Treatment With MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects (MYSTICOL)          US WorldMeds, LLC          Role: <u>Site Principal Investigator</u></p>
02/03/15 - 06/30/17	<p>SD-809 C-17. This is a Phase I trial of deutetrabenazine to evaluate safety, pharmacokinetics, and potential efficacy of deutetrabenazine in pediatric Tourette syndrome.          Teva          Role: <u>Site Principal Investigator</u></p>
01/15/15 - 12/31/17	<p>Auspex TD C-23. The purpose of this study is to determine whether an investigational drug, SD-809 (deutetrabenazine), will reduce the severity of abnormal involuntary movements of tardive dyskinesia.          Auspex          Role: <u>Site Principal Investigator</u></p>
08/01/14 - 04/01/16	<p>STEADY PD (Safety, Tolerability, and Efficacy Assessment of Dynacirc® CR for PD). The goal of this phase III trial is to determine whether isradapine slows progression of early stage Parkinson disease.          Principal Investigator(s): Kevin Biglan and Tanya Simuni          National Institute of Neurological Disorders and Stroke (NINDS)          Role: <u>Site Principal Investigator</u></p>
07/01/14 - 12/31/16	<p>SD-809 C-20. This is an open label long-term safety/efficacy extension of the C-18 and C-23 protocols.          Principal Investigator(s): David R. Shprecher          Teva          Role: <u>Site Principal Investigator</u></p>
07/01/14 - 06/01/16	<p>SD-809 C-18. The purpose of this study is to determine whether an investigational drug, SD-809 (deutetrabenazine), will reduce the severity of abnormal involuntary movements of tardive dyskinesia.          Principal Investigator(s): David R. Shprecher          Teva          Role: <u>Site Principal Investigator</u></p>
05/13/14 - 12/31/14	<p>A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy          Principal Investigator(s): David R. Shprecher          Lundbeck          Role: <u>Site Principal Investigator</u></p>
05/01/14 - 11/01/16	<p>PRIDE-HD: A Phase 2 trial Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease.          The main goal of this study is to test whether Pridopidine helps with the signs and symptoms of Huntington's Disease.</p>



	Principal Investigator(s): Andrew McGarry and Karl Kiebturtz Teva Pharmaceutical Industries Ltd. Role: <u>Site Principal Investigator</u>
03/01/14 - 02/01/16	ARC HD The main goal of this study is to test an extended release investigational drug and its ability to treat chorea. Principal Investigator(s): David R. Shprecher Auspex Pharmaceuticals Role: <u>Site Principal Investigator</u>
12/01/13 - 09/30/14	FIRST HD A randomized double blind placebo controlled study of SD-809 extended release for the treatment of chorea associated with Huntington disease Principal Investigator(s): David R. Shprecher; Claudia Testa; Sam Frank Auspex Pharmaceuticals Role: <u>Site Principal Investigator</u>
01/01/13 - 12/31/14	Randomized controlled study of rotigotine for apathy and motor symptoms of Parkinson disease UCB Pharma Inc Role: <u>Site Principal Investigator</u>
01/01/13 - 12/31/14	A 24-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Add-on, Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease Teva Neuroscience Role: <u>Site Principal Investigator</u>
08/01/12 - 03/31/16	Randomized controlled trial of aripiprazole in pediatric Tourette syndrome Otsuka America Pharmaceutical Inc Role: <u>Site Principal Investigator</u>
07/01/11 - 02/05/16	ENROLL-HD The main goal of this study is to provide the international HD research community with a rich clinical dataset and cohort to enable and support design and conduct of clinical trials. Principal Investigator: Bernhard Landwehrmeyer Cure Huntington's Disease Initiative Foundation Role: <u>Site Principal Investigator</u>
07/01/11 - 02/01/13	Open label extension study of pimavanserin for Parkinson disease psychosis Principal Investigator(s): David R. Shprecher Acadia Pharmaceuticals Role: <u>Site Principal Investigator</u>
06/01/11 - 12/31/13	Phase II study of Cogane in Early-stage Parkinson's Disease Principal Investigator(s): David R. Shprecher; Karl Kiebturtz; Warren Olanow Phytopharm Plc Role: <u>Site Principal Investigator</u>
06/01/11 - 12/31/12	Phase III trial of pimavanserin for Parkinson disease psychosis Principal Investigator(s): David R. Shprecher Acadia Pharmaceuticals Role: <u>Site Principal Investigator</u>
04/01/11 - 06/30/15	Parkinson's Genetic Research Study (PaGeR)

	Principal Investigator: Cyrus Zabetian NINDS Role: <u>Site Principal Investigator</u>
07/01/10 - 12/31/14	CREST-E Creatine Safety, Tolerability, & Efficacy in Huntington's Disease Principal Investigator(s): David R. Shprecher; Steve Hersch; Steven Hersch NCCAM Role: <u>Site Principal Investigator</u>
07/01/10 - 06/30/11	Cooperative Huntington's Observational Research Trial (COHORT) Principal Investigator(s): David R. Shprecher University of Rochester Role: <u>Site Principal Investigator</u>
06/01/10 - 12/31/12	Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy Principal Investigator: Adam Boxer Allon Therapeutics, Inc Role: <u>Site sub-Investigator</u>
05/26/10 - 02/01/12	Genetic and Environmental Risk Factors for PSP Principal Investigator(s): Irene Litvan University of Louisville Role: <u>Site Principal Investigator</u>
01/01/07 - 06/30/09	NET-PD LS-1 Creatine in Parkinson's Disease Principal Investigator(s): Karl Kieburtz, MD, MPH National Institute of Neurological Disorders and Stroke Role: <u>Medical Monitor</u>
01/01/07 - 06/30/09	2CARE: A Treatment Trial of Coenzyme Q10 in Huntington's Disease Principal Investigator(s): David R. Shprecher; Merit Cudkowicz; Peter Como, PhD High Q Foundation, Inc. Role: <u>Site Principal Investigator</u>
01/01/07 - 06/30/09	Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria Boehringer Ingelheim Role: <u>Site sub-Investigator</u>
01/01/07 - 05/01/09	A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis ACADIA Pharmaceuticals Inc. Role: <u>Site sub-Investigator</u>

## **TEACHING RESPONSIBILITIES/ASSIGNMENTS**

### **Course and Curriculum Development**

2009 - 2015	Movement Disorders Rotation, University of Utah Department of Neurology. Organized rotation curriculum/logistics including 12-16 lectures divided among three or more faculty for neurology residents (class of 10+).
-------------	---

2018 - Present Movement Disorders Rotation, Banner University Medical Center-Phoenix. Organized rotation curriculum/logistics including resident lectures divided among three or more faculty for neurology residents.

### **Mentoring/Advising**

#### PhD/Doctorate

2014 Advisor/Mentor, Daniel Ryskamp, University of Utah, Clinical mentor to student while completing his MSci/neuroscience PhD  
*Trainee's Current Career Activities:* Completing a post-doc focused on Huntington's disease research in Ilya Bezprozvanny's lab at University of Texas

#### Medical Student

2009 - 2012 Advisor/Mentor, John Bautista, University of Utah, Clinical Research Advisor during medical school.  
*Trainee's Current Career Activities:* Practicing Internal Medicine Physician

#### Undergraduate

2019 Advisor/Mentor, Namitha Palnati, Banner Sun Health Research Institute, Research volunteer/shadow in clinic  
*Trainee's Current Career Activities:* Kansas College of Osteopathic Medicine Class of 2026

2014 - 2015 Advisor/Mentor, Aaron Adler, University of Utah, Premedical advisor to student while he was shadowing in clinic.  
*Trainee's Current Career Activities:* University of Utah School of Medicine class of 2019. University of Colorado Anesthesiology Residency 2020-24.

2013 Advisor/Mentor, Kyle Roller, University of Utah, Premedical advisor to student while he was shadowing in clinic.  
*Trainee's Current Career Activities:* Psychiatrist

2012 - 2013 Supervisor, Michael Graves, University of Utah, Work-Study Research Assistant  
*Trainee's Current Career Activities:* Des Moines College of Osteopathic Medicine, class of 2022.

2012 - 2013 Supervisor, Tracey Fan, University of Utah, Work Study Research Assistant  
*Trainee's Current Career Activities:* Touro University Nevada College of Osteopathic Medicine, class of 2017. Neurologist, Critical Care Fellow at Massachusetts General Hospital.

2012 - 2013 Supervisor, Natalie Eggleston, University of Utah, Volunteer research assistant  
*Trainee's Current Career Activities:* University of Washington School of Medicine, class of 2019. Obstetrics & gynecology residency, Santa Clara Valley Medical Center

2011 Advisor/Mentor, Alex Coffman, University of Utah, Premedical advisor to student while shadowing in clinic.

	<i>Trainee's Current Career Activities:</i> University of Vermont College of Medicine, class of 2016. Radiation Oncologist
2011 - 2012	Advisor/Mentor, Karli McMillan, University of Utah, Premedical advisor while student was shadowing in clinic.
	<i>Trainee's Current Career Activities:</i> Lincoln Memorial University-DeBusk College of Osteopathic Medicine class of 2017. Family Medicine Physician.
2011	Supervisor, Nick Hovda, University of Utah, Volunteer research assistant.
	<i>Trainee's Current Career Activities:</i> University of Washington School of Medicine, Class of 2018. Psychiatrist.
2010 - 2013	Supervisor, Maria North, University of Utah, Parkinson's Disease Study Coordinator.
	<i>Trainee's Current Career Activities:</i> Touro College of Osteopathic Medicine, Class of 2018. Family Medicine Physician.
2009 - 2012	Supervisor, Ashley Brown, University of Utah, Work-study research assistant.
	<i>Trainee's Current Career Activities:</i> Lake Erie College of Osteopathic Medicine-Seton Hill, class of 2017. General Surgeon.

### **Graduate Student Committees**

2012 - 2016	Member, Terrie Vann Vann Ward, University of Utah School of Nursing
-------------	---

### **Didactic Lectures**

2016 - Present	Movement Disorders Overview, Annual Neurology Curriculum, Banner University Medical Center-Phoenix, Internal Medicine Residency, Phoenix, AZ
2010 - 2015	PM&R Movement Disorders Lectures (two per year)
2009 - 2015	Physical Therapy School Movement Disorders lectures (two per year)
2009 - 2015	Neurology Residency Movement Disorders Curriculum

### **Internal Teaching Experience**

2011 - 2013	Neuropsychiatric Movement and Associated Disorders working group, University of Utah Brain Institute.
-------------	---

### **PEER-REVIEWED JOURNAL ARTICLES**

1. Choudhury P, Zhang N, Adler CH, Chen K, Belden C, Driver-Dunckley E, Mehta SH, Shprecher DR, Serrano GE, Shill HA, Beach TG, Atri A. Longitudinal motor decline in dementia with Lewy bodies, Parkinson disease dementia, and Alzheimer's dementia in a community autopsy cohort. *Alzheimers Dement.* 2023 Oct;19(10):4377-4387.
2. Levendowski DJ, Neylan TC, Lee-Iannotti JK, Timm PC, Guevarra C, Angel E, Shprecher D, Mazeika G, Walsh CM, Boeve BF, St Louis EK. The Accuracy and Reliability of Sleep Staging and Sleep Biomarkers in Patients with Isolated Rapid Eye Movement Sleep Behavior Disorder. *Nat Sci Sleep.* 2023 May 3;15:323-331.
3. Elliott JE, Lim MM, Keil AT, Postuma RB, Pelletier A, Gagnon JF, St Louis EK, Forsberg LK, Fields JA, Huddleston DE, Bliwise DL, Avidan AY, Howell MJ, Schenck CH, McLeland J,

Criswell SR, Videnovic A, During EH, Miglis MG, **Shprecher DR**, Lee-Iannotti JK, Boeve BF, Ju YS, North American Prodromal Synucleinopathy (NAPS) Consortium (2023). Baseline characteristics of the North American prodromal Synucleinopathy cohort. *Ann Clin Transl Neurol.* 2023 Apr; 10(4):52-535.

4. Camilleri M, Subramanian T, Pagan F, Isaacson S, Gil R, Hauser RA, Feldman M, Goldstein M, Kumar R, Truong D, Chhabria N, Walter BL, Eskenazi J, Riesenberger R, Burdick D, Tse W, Molho E, Robottom B, Bhatia P, Kadimi S, Klos K, **Shprecher D**, Marquez-Mendoza O, Hidalgo G, Grill S, Li G, Mandell H, Hughes M, Stephenson S, Vandersluis J, Pfeffer M, Duker A, Shivkumar V, Kinney W, MacDougall J, Zasloff M, Barbut D (2022). Oral ENT-01 Targets Enteric Neurons to Treat Constipation in Parkinson Disease : A Randomized Controlled Trial. *Ann Intern Med*, 175 (12), 1666-1674.
5. Levendowski DJ, Walsh CM, Boeve BF, Tsuang D, Hamilton JM, Salat D, Berka C, Lee-Iannotti JK, **Shprecher D**, Westbrook PR, Mazeika G, Yack L, Payne S, Timm PC, Neylan TC, St Louis EK (2022). Non-REM sleep with hypertonia in Parkinsonian Spectrum Disorders: A pilot investigation. *Sleep Med*, 100, 501-510.
6. Serrano GE, Walker JE, Tremblay C, Piras IS, Huentelman MJ, Belden CM, Goldfarb D, **Shprecher D**, Atri A, Adler CH, Shill HA, Driver-Dunckley E, Mehta SH, Caselli R, Woodruff BK, Haarer CF, Ruhlen T, Torres M, Nguyen S, Schmitt D, Rapsack SZ, Bime C, Peters JL, Alevritis E, Arce RA, Glass MJ, Vargas D, Sue LI, Intorcica AJ, Nelson CM, Oliver J, Russell A, Suszczewicz KE, Borja CI, Cline MP, Hemmingsen SJ, Qiji S, Hobgood HM, Mizgerd JP, Sahoo MK, Zhang H, Solis D, Montine TJ, Berry GJ, Reiman EM, Röltgen K, Boyd SD, Pinsky BA, Zehnder JL, Talbot P, Desforges M, DeTure M, Dickson DW, Beach TG (2022). SARS-CoV-2 Brain Regional Detection, Histopathology, Gene Expression, and Immunomodulatory Changes in Decedents with COVID-19.(Epub ahead of print). *J Neuropathol Exp Neurol*.
7. Martino D, Malaty I, Müller-Vahl K, Nosratmirshekarlou E, Pringsheim TM, **Shprecher D**, Ganos C, Movement Disorders Society Tourette Syndrome Study Group. (2021). Treatment failure in persistent tic disorders: an expert clinicians' consensus-based definition.(Epub ahead of print). *Eur Child Adolesc Psychiatry*.
8. Ganos C, Sarva H, Kurvits L, Gilbert DL, Hartmann A, Worbe Y, Mir P, Müller-Vahl KR, Münchau A, **Shprecher D**, Singer HS, Deeb W, Okun MS, Malaty IA, Hallett M, Tijssen MA, Pringsheim T, Martino D, Tic Disorders and Tourette Syndrome Study Group of the International Parkinson and Movement Disorder Society. (2021). Clinical Practice Patterns in Tic Disorders Among Movement Disorder Society Members. *Tremor Other Hyperkinet Mov (N Y)*, 11, 43.
9. Parkinson Study Group SURE-PD3 Investigators. (2021). Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. *JAMA*, 326(10), 926-939.
10. Adler CH, Beach TG, Zhang N, Shill HA, Driver-Dunckley E, Mehta SH, Atri A, Caviness JN, Serrano G, **Shprecher DR**, Sue LI, Belden CM (2021). Clinical Diagnostic Accuracy of Early/Advanced Parkinson Disease: An Updated Clinicopathologic Study. *Neurol Clin Pract*, 11(4), e414-e421.
11. Litvan I, Proudfoot JA, Martin ER, Standaert D, Riley D, Hall D, Marras C, Bayram E, Dubinsky RM, Bordelon Y, Reich S, **Shprecher D**, Kluger B, Cunningham C, Schellenberg GD, Jankovic J (2021). Gene-Environment Interactions in Progressive Supranuclear Palsy. *Front Neurol*, 12, 664796.

12. Rezvanian S, Litvan I, Standaert D, Jankovic J, Reich SG, Hall D, **Shprecher DR**, Bordelon Y, Dubinsky R, Kluger B (2020). Understanding the relationship between freezing of gait and other progressive supranuclear palsy features. *Parkinsonism Relat Disord*, 78, 56-60.
13. Bayram E, Marras C, Standaert DG, Kluger BM, Bordelon YM, **Shprecher DR**, Litvan I, ENGENE-PSP Consortium. (2020). Progressive Supranuclear Palsy and Statin Use. *Mov Disord*, 35 (7), 1253-1257.
14. Parkinson Study Group STEADY-PD III Investigators (2020). Isradipine Versus Placebo in Early Parkinson Disease: A Randomized Trial. *Ann Intern Med*, 172(9), 591-598.
15. **Shprecher DR**, Adler CH, Zhang N, Shill HA, Belden CM, Driver-Dunckley E, Mehta SH, Davis KJ, Sue LI, Zamrini E, Beach TG (2020). Do Parkinson disease subject and caregiver-reported Epworth sleepiness scale responses correlate? *Clin Neurol Neurosurg*, 192, 105728.
16. Beach TG, Adler CH, Zhang N, Serrano GE, Sue LI, Driver-Dunckley E, Mehta SH, Zamrini EE, Sabbagh MN, Shill HA, Belden CM, **Shprecher DR**, Caselli RJ, Reiman EM, Davis KJ, Long KE, Nicholson LR, Intorcchia AJ, Glass MJ, Walker JE, Callan MM, Oliver JC, Arce R, Gerkin RC (2020). Severe hyposmia distinguishes neuropathologically confirmed dementia with Lewy bodies from Alzheimer's disease dementia. *PLoS One*, 15(4), e0231720.
17. **Shprecher DR**, Serrano GE, Zhang N, Intorcchia A, Davis KJ, Glass M, Curry J, Walker J, Cutler B, Callan M, Garcia A, Sue LI, Beach TG (2020). Prevalence of REM sleep behavior disorder in Sun City, Arizona. *Heliyon*, 6(1), e03140.
18. Serrano GE, **Shprecher D**, Callan M, Cutler B, Glass M, Zhang N, Walker J, Intorcchia A, Adler CH, Shill HA, Driver-Dunckley E, Mehta SH, Belden CM, Zamrini E, Sue LI, Vargas D, Beach TG (2020). Cardiac sympathetic denervation and synucleinopathy in Alzheimer's disease with brain Lewy body disease. *Brain Commun*, 2(1), fcaa004.
19. Fernandez HH, Stamler D, Davis MD, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Woods SW, Bega D, LeDoux MS, **Shprecher DR**, Anderson KE (2019). Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. *J Neurol Neurosurg Psychiatry*, 90(12), 1317-1323.
20. Simuni T, Uribe L, Cho HR, Caspell-Garcia C, Coffey CS, Siderowf A, Trojanowski JQ, Shaw LM, Seibyl J, Singleton A, Toga AW, Galasko D, Foroud T, Tosun D, Poston K, Weintraub D, Mollenhauer B, Tanner CM, Kieburtz K, Chahine LM, Reimer A, Hutten SJ, Bressman S, Marek K; PPMI Investigators (2019). Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. *Lancet Neurol*, 19(1), 71-80.
21. Shoeibi A, Litvan I, Juncos JL, Bordelon Y, Riley D, Standaert D, Reich SG, **Shprecher D**, Hall D, Marras C, Kluger B, Olfati N, Jankovic J (2019). Are the International Parkinson disease and Movement Disorder Society progressive supranuclear palsy (IPMDS-PSP) diagnostic criteria accurate enough to differentiate common PSP phenotypes? *Parkinsonism Relat Disord*, 69, 34-39.
22. Adler CH, Beach TG, Zhang N, Shill HA, Driver-Dunckley E, Caviness JN, Mehta SH, Sabbagh MN, Serrano GE, Sue LI, Belden CM, Powell J, Jacobson SA, Zamrini E, **Shprecher D**, Davis KJ, Dugger BN, Hentz JG (2019). Unified Staging System for Lewy Body Disorders: Clinicopathologic Correlations and Comparison to Braak Staging. *J Neuropathol Exp Neurol*, 78(10), 891-899.
23. Rabadia SV, Litvan I, Juncos J, Bordelon Y, Riley DE, Standaert D, Reich SG, Hall DA, Kluger B, **Shprecher D**, Marras C, Jankovic J (2019). Hypertension and progressive supranuclear palsy. *Parkinsonism Relat Disord*, 66, 166-170.

24. Fernandez HH, Stamler D, Davis MD, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Woods SW, Bega D, LeDoux MS, **Shprecher DR**, Anderson KE (2019). Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. *J Neurol Neurosurg Psychiatry*, 90(12), 1317-1323.
25. Malek-Ahmadi M, Beach TG, Zamrini E, Adler CH, Sabbagh MN, Shill HA, Jacobson SA, Belden CM, Caselli RJ, Woodruff BK, Rapsack SZ, Ahern GL, Shi J, Caviness JN, Driver-Dunckley E, Mehta SH, **Shprecher DR**, Spann BM, Tariot P, Davis KJ, Long KE, Nicholson LR, Intorcchia A, Glass MJ, Walker JE, Callan M, Curry J, Cutler B, Oliver J, Arce R, Walker DG, Lue LF, Serrano GE, Sue LI, Chen K, Reiman EM (2019). Faster cognitive decline in dementia due to Alzheimer disease with clinically undiagnosed Lewy body disease. *PLoS One*, 14(6), e0217566.
26. **Shprecher D**, Zhang N, Halverson M, Savica R (2019). Parkinsonism Risk Factors in Salt Lake City, Utah: A Community-Based Study. *Brain Sci*, 9(3).
27. Reilmann R, McGarry A, Grachev ID, Savola JM, Borowsky B, Eyal E, Gross N, Langbehn D, Schubert R, Wickenberg AT, Papapetropoulos S, Hayden M, Squitieri F, Kiebertz K, Landwehrmeyer GB, European Huntington's Disease Network, HuntingtonStudy Group investigators. (2018 Dec 14 [Epub ahead of print]). Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. *Lancet Neurol*.
28. Barrell K, Bureau B, Turcano P, Phillips GD, Anderson JS, Malik A, **Shprecher D**, Zorn M, Zamrini E, Savica R (2018). High-Order Visual Processing, Visual Symptoms, and Visual Hallucinations: A Possible Symptomatic Progression of Parkinson's Disease. *Front Neurol*, 9, 999.
29. **Shprecher DR**, Adler CH, Zhang N, Hentz JG, Serrano GE, Dugger BN, Shill HA, Savica R, Caviness JN, Sabbagh MN, Belden CM, Driver-Dunckley E, Mehta SH, Sue LI, Davis KJ, Zamrini E, Beach TG (2018). Predicting alpha-synuclein pathology by REM sleep behavior disorder diagnosis. *Parkinsonism Relat Disord*, 55, 92-96.
30. Savica R, Beach TG, Hentz JG, Sabbagh MN, Serrano GE, Sue LI, Dugger BN, Shill HA, Driver-Dunckley E, Caviness JN, Mehta SH, Jacobson SA, Belden CM, Davis KJ, Zamrini E, **Shprecher DR**, Adler CH. doi:10.1111/ane.13028. [Epub ahead of print] (09/19/2018). Lewy body pathology in Alzheimer's disease: A clinicopathological prospective study. *Acta Neurol Scand*.
31. Park HK, Ilango S, Charriez CM, Checkoway H, Riley D, Standaert DG, Bordelon Y, **Shprecher DR**, Reich SG, Hall D, Kluger B, Marras C, Jankovic J, Dubinsky R, Litvan I, ENGINE-PSP Study. (2018). Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study. *Mov Disord*, 33(3), 468-472.
32. Marras C, Cunningham CR, Hou J, Proudfoot J, Standaert DG, Juncos J, Riley D, Reich SG, Hall D, Kluger B, Bordelon Y, **Shprecher DR**, Litvan I, for ENGINE-PSP. (2017). Anti-inflammatory drug use and progressive supranuclear palsy. *Parkinsonism Relat Disord*, 48, 89-92.
33. Schobel SA, Palermo G, Auinger P, Long JD, Ma S, Khwaja OS, Trundell D, Cudkovicz M, Hersch S, Sampaio C, Dorsey ER, Leavitt BR, Kiebertz KD, Sevigny JJ, Langbehn DR, Tabrizi SJ, TRACK-HD, COHORT, CARE-HD, and 2CARE Huntington Study Group Investigators (12/12/2017). Motor, cognitive, and functional declines contribute to a single progressive factor in early HD. *Neurology*, 89(24), 2495-2502.
34. Gerstenecker A, Roberson ED, Schellenberg GD, Standaert DG, **Shprecher DR**, Kluger BM, Litvan I (2017). Genetic influences on cognition in progressive supranuclear palsy. *Mov Disord*, 32 (12), 1764-1771.

35. Fernandez HH, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Meltzer HY, Woods SW, Bega D, LeDoux MS, **Shprecher DR**, Davis C, Davis MD, Stamler D, Anderson KE (2017). Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study. *Neurology*, 88(21), 2003-2010.
36. Bluett B, Litvan I, Cheng S, Juncos J, Riley DE, Standaert DG, Reich SG, Hall DA, Kluger B, **Shprecher D**, Marras C, Jankovic J, ENGENE PSP study. (2017). Understanding falls in progressive supranuclear palsy. *Parkinsonism Relat Disord*, 35, 75-81.
37. McGarry A, McDermott M, Kiebertz K, de Blicke EA, Beal F, Marder K, Ross C, Shoulson I, Gilbert P, Mallonee WM, Guttman M, Wojcieszek J, Kumar R, LeDoux MS, Jenkins M, Rosas HD, Nance M, Biglan K, Como P, Dubinsky RM, Shannon KM, O'Suilleabhain P, Chou K, Walker F, Martin W, Wheelock VL, McCusker E, Jankovic J, Singer C, Sanchez-Ramos J, Scott B, Suchowersky O, Factor SA, Higgins DS Jr, Molho E, Revilla F, Caviness JN, Friedman JH, Perlmutter JS, Feigin A, Anderson K, Rodriguez R, McFarland NR, Margolis RL, Farbman ES, Raymond LA, Suski V, Kostyk S, Colcher A, Seeberger L, Epping E, Esmail S, Diaz N, Fung WL, Diamond A, Frank S, Hanna P, Hermanowicz N, Dure LS, Cudkowicz M, Huntington Study Group 2CARE Investigators and Coordinators (12/2/2016). A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. *Neurology*, Epub Dec 2 2016.
38. Jankovic J, Jimenez-Shahed J, Budman C, Coffey B, Murphy T, **Shprecher D**, Stamler D (11/8/2016). Deutetrabenazine in tics associated with Tourette syndrome. *Tremor Other Hyperkinet Mov (N Y)*, 6.
39. Kious BM, Jimenez-Shahed J, **Shprecher DR** (2016). Treatment-refractory Tourette Syndrome. *Prog Neuropsychopharmacol Biol Psychiatry*, 70, 227-36.
40. Huntington Study Group., Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, Kinell S, Leavitt B, Oakes D, O'Neill C, Vaughan C, Goldstein J, Herzog M, Snively V, Whaley J, Wong C, Suter G, Jankovic J, Jimenez-Shahed J, Hunter C, Claassen DO, Roman OC, Sung V, Smith J, Janicki S, Clouse R, Saint-Hilaire M, Hohler A, Turpin D, James RC, Rodriguez R, Rizer K, Anderson KE, Heller H, Carlson A, Criswell S, Racette BA, Revilla FJ, Nucifora F Jr, Margolis RL, Ong M, Mendis T, Mendis N, Singer C, Quesada M, Paulsen JS, Brashers-Krug T, Miller A, Kerr J, Dubinsky RM, Gray C, Factor SA, Sperin E, Molho E, Eglow M, Evans S, Kumar R, Reeves C, Samii A, Chouinard S, Beland M, Scott BL, Hickey PT, Esmail S, Fung WL, Gibbons C, Qi L, Colcher A, Hackmyer C, McGarry A, Klos K, Gudesblatt M, Fafard L, Graffitti L, Schneider DP, Dhall R, Wojcieszek JM, LaFaver K, Duker A, Neefus E, Wilson-Perez H, **Shprecher D**, Wall P, Blindauer KA, Wheeler L, Boyd JT, Houston E, Farbman ES, Agarwal P, Eberly SW, Watts A, Tariot PN, Feigin A, Evans S, Beck C, Orme C, Edicola J, Christopher E (2016). Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. *JAMA*, 316(1), 40-50.
41. Litvan I, Lees PS, Cunningham CR, Rai SN, Cambon AC, Standaert DG, Marras C, Juncos J, Riley D, Reich S, Hall D, Kluger B, Bordelon Y, **Shprecher DR**, for ENGENE-PSP. (2016). Environmental and occupational risk factors for progressive supranuclear palsy: Case-control study. *Mov Disord*, 31(5), 644-52.
42. Brody DM, Litvan I, Warner S, Riley DE, Hall DA, Kluger BM, **Shprecher DR**, Cunningham CR (2016). Relationship between uric acid levels and progressive supranuclear palsy. *Mov Disord*, 31 (5), 663-7.
43. **Shprecher D**, Kious B, Himle M (11/27/15). Advances in Mechanistic Understanding and Treatment Approaches to Tourette Syndrome. *Discov Med*, 20(111).



44. Mata IF, Jang Y, Kim CH, Hanna DS, Dorschner MO, Samii A, Agarwal P, Roberts JW, Klepitskaya O, **Shprecher DR**, Chung KA, Factor SA, Espay AJ, Revilla FJ, Higgins DS, Litvan I, Leverenz JB, Yearout D, Inca-Martinez M, Martinez E, Thompson TR, Cholerton BA, Hu SC, Edwards KL, Kim KS, Zabetian CP (2015). The RAB39B p.G192R mutation causes X-linked dominant Parkinson's disease. *Mol Neurodegener*, 10, 50.
45. Writing Group for the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators, Kieburtz K, Tilley BC, Elm JJ, et al (2/10/2015). Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. *JAMA*, 313(6), 584-93.
46. **Shprecher D**, Rubenstein L, Gannon K, Frank S, Kurlan R (2014). Temporal Course of the Tourette Syndrome Clinical Triad. *Tremor Other Hyperkinet Mov (N Y)*.
47. **Shprecher D**, Schrock L, Himle M (2014). Neurobehavioral aspects, pathophysiology, and management of Tourette's syndrome. *Curr Opin Neurol*, 27(4), 484-92.
48. **Shprecher D**, Gannon K, Agarwal N, Shi X, Anderson J (2014). Elucidating the mechanism of tic improvement in Tourette syndrome: a pilot study. *Tremor Other Hyperkinet Mov (N Y)*.
49. Duff K, **Shprecher D**, Litvan I, Gerstenecker A, Mast B on behalf of the ENGENE investigators (2013). Correcting for demographic variables on the modified Telephone Interview for Cognitive Status. *Am J Geriatr Psychiatry*.
50. Elm JJ, NINDS NET-PD Investigators (2012 Oct;27). Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. *Mov Disord*, 27(12), 1512-21.
51. **Shprecher D**, Noyes Katia, Biglan Kevin, Wang Dongwen, Dorsey Ray E, Kurlan Roger, Adams Michael Jacob (2012). Willingness of Parkinson Disease Patients to Participate in Research Using Internet Based Technology. *Telemed J E Health*.
52. Dorsey ER, Voss TS, **Shprecher DR**, Deuel LM, Beck CA, Gardiner IF, Coles MA, Burns RS, Marshall FJ, Biglan KM (2010). A U.S. survey of patients with Parkinson's disease: satisfaction with medical care and support groups. *Mov Disord*, 25(13), 2128-35.
53. **Shprecher D**, Silberstein H, Kurlan R (2010 Jun 15). Propriospinal myoclonus due to cord compression in the absence of myelopathy. *Mov Disord*, 25(8), 1100-1.
54. **Shprecher D**, Mehta L (2010). The syndrome of delayed post-hypoxic leukoencephalopathy. *NeuroRehabilitation*, 26(1), 65-72.
55. **Shprecher D**, Kurlan R (2009). The management of tics. *Mov Disord*, 24(1), 15-24.
56. **Shprecher DR**, Flanigan KM, Smith AG, Smith SM, Schenkenberg T, Steffens J (2008). Clinical and diagnostic features of delayed hypoxic leukoencephalopathy. *J Neuropsychiatry Clin Neurosci*, 20(4), 473-7.
57. **Shprecher D**, Schwalb J, Kurlan R (2008). Normal pressure hydrocephalus: diagnosis and treatment. *Curr Neurol Neurosci Rep*, 8(5), 371-6.

## **REVIEW ARTICLES**

1. Lyon G, **Shprecher D**, Coffey B, Kurlan R (2010). Tourette's Disorder. [Review]. *Curr Treat Options Neurol*, 12, (4), 274-286.

## **BOOK CHAPTERS**

1. Hayes L, Himle M, Ramanujam K, **Shprecher D** (2015). Tourette Syndrome and Other Tic Disorders. In Kapalka G (Ed.), *Treating Disruptive Disorders: A Guide to Psychological, Pharmacological, and Combined Therapies* Routledge.
2. David Shprecher (2/15/2017). Tics and Tourette Syndrome. In Hall, Deborah / Barton, Brandon (Eds.), *Non-Parkinsonian Movement Disorders* Wiley & Sons Ltd.
3. Roger Kurlan and David Shprecher (2011). Tics and Tourette syndrome. In Néstor Gálvez-Jiménez and Paul Tuite (Eds.), *Uncommon Causes of Movement Disorders* Cambridge University Press.
4. **Shprecher D**, Kurlan R (2010). Simple tics. In Komploti K and Verhagen L (Eds.), *The Encyclopedia of Movement Disorders* Elsevier.
5. **Shprecher D**, Kurlan R (2010). Complex tics. In Komploti K and Verhagen L (Eds.), *The Encyclopedia of Movement Disorders* Elsevier.

## **ADDITIONAL PUBLICATIONS**

### **Case Reports**

1. Jones KB, Allred J, **Shprecher D** (2017). Muscle spasms, twitches in arm upon throwing . Dx? *J Fam Pract*, 66(4), 234-236.
2. **Shprecher D**, Grossmann K, Tward J (2014). Sustained remission of Parkinson disease associated melanoma with immunotherapy. *Parkinsonism Relat Disord*.
3. **Shprecher D**, Sloan C, Sederholm, B (5/2/2013). Neuropsychiatric side effects of cyclobenzaprine. *BMJ Case Rep*, (5/2/2013).
4. **Shprecher D** (2012). Sensory Trick with Metoclopramide associated Tardive Tremor. *BMJ Case Rep*.
5. **Shprecher D**, Frech T, Chin S, Eskandari R, Steffens J (2008). Progressive multifocal leucoencephalopathy associated with lupus and methotrexate overdose. *Lupus*, 17(11), 1029-32.

### **Editorials**

1. **Shprecher DR**, Majersik JJ (2017). The virtual house call: A 21st-century innovation in the care of patients with Parkinson disease. *Neurology*, 89(11), 1103-1104.

### **Letters**

1. **Shprecher DR**, Derkinderen P. (2012). Parkinson disease: the enteric nervous system spills its guts. [Letter to the editor]. *Neurology*, 78(9), 683.

### **Others**

1. Serrano GE, Walker JE, Arce R, Glass MJ, Vargas D, Sue LI, Intorcchia AJ, Nelson CM, Oliver J, Papa J, Russell A, Suszczewicz KE, Borja CI, Belden C, Goldfarb D, **Shprecher D**, Atri A, Adler CH, Shill HA, Driver-Dunckley E, Mehta SH, Readhead B, Huentelman MJ, Peters JL, Alevritis E, Bimi C, Mizgerd JP, Reiman EM, Montine TJ, Desforges M, Zehnder JL, Sahoo MK, Zhang H, Solis D, Pinsky BA, Deture M, Dickson DW, Beach TG

(2021). Mapping of SARS-CoV-2 Brain Invasion and Histopathology in COVID-19 Disease. *medRxiv* United States.

2. Beach TG, Russell A, Sue LI, Intorcchia AJ, Glass MJ, Walker JE, Arce R, Nelson CM, Hidalgo T, Chiarolanza G, Mariner M, Scroggins A, Pullen J, Souders L, Sivananthan K, Carter N, Saxon-LaBelle M, Hoffman B, Garcia A, Callan M, Fornwalt BE, Carew J, Filon J, Cutler B, Papa J, Curry JR, Oliver J, **Shprecher D**, Atri A, Belden C, Shill HA, Driver-Dunckley E, Mehta SH, Adler CH, Haarer CF, Ruhlen T, Torres M, Nguyen S, Schmitt D, Fietz M, Lue LF, Walker DG, Mizgerd JP, Serrano GE (2021). Increased Risk of Autopsy-Proven Pneumonia with Sex, Season and Neurodegenerative Disease. *medRxiv* United States.

## **ORAL PRESENTATIONS**

### **Keynote/Plenary Lectures**

#### National

- 2019 Are Lewy bodies associated with sympathetic pathology in dementia subjects? Parkinson Study Group, 32nd Annual Symposium on the Etiology, Pathogenesis, and Treatment of Parkinson Disease and Other Movement Disorders, Phoenix, AZ, USA

### **Meeting Presentations**

#### International

- 2019 Predicting alpha-synuclein pathology by REM sleep behavior disorder diagnosis. International REM Sleep Behavior Disorder Study Group, Copenhagen, Denmark.
- 2019 Prevalence of REM Sleep Behavior Disorder in Sun City, AZ. International Lewy Body Dementia Conference/Cleveland Clinic, Las Vegas, Nevada, USA

#### National

- 2023 How to be a Rock Star for Tic and Tourette Patients. Tourette Association of America. Webcast: <https://www.youtube.com/watch?v=9tTFE3UjOa8>
- 2023 Tics and Tourette: How to Talk to Clinicians and What to Expect. Tourette Association of America. Webcast: [https://www.youtube.com/watch?v=iyEw\\_vYY8cM&t=1586s](https://www.youtube.com/watch?v=iyEw_vYY8cM&t=1586s)
- 2020 - Present Lewy body and Related Dementias. Alzheimer's, Lewy body and Related Dementias/Banner Sun Health Research Institute, Sun City, AZ

#### Local/Regional

- 2023 Advances in Essential Tremor and Atypical Parkinsonism, Advanced Therapeutics of Movement and Related Disorders, Washington, D.C.

- 2022 Emerging Therapies for Parkinson's Plus Syndromes, Advanced Therapeutics of Movement and Related Disorders, Washington, D.C.
- 2018 The Heart of the Matter: Separating Lewy Body Dementia from AD using Tissue from the Brain and Body Donation Program. Arizona Alzheimer's Consortium, Phoenix, AZ.
- 2018 New and Emerging Treatments for Hyperkinetic Disorders, University of Arizona, Neuroscience Symposium- 2017, Phoenix, AZ.
- 2017 Overview of Pediatric Movement Disorders, Mind Matters: Arizona Psychiatric Society Annual Meeting, Tempe, AZ
- 2017 New and Emerging Treatments for Parkinson Disease, University of Arizona, Neuroscience Symposium- 2017, Phoenix, AZ
- 2017 Adult Tourette Syndrome. Texas Tourette Symposium, United Way of Greater Houston, TX.
- 2017 Assessment of Tourette Symptoms. Texas Tourette Symposium, United Way of Greater Houston, TX.
- 2016 The Arizona Study of Aging and Neurodegenerative Disease, Oregon Health Sciences University, Northwest Basal Ganglia Coterie, Mt. Hood, OR
- 2014 Neuroprotection trials in populations enriched for Parkinson disease risk. OHSU, Northwest Basal Ganglia Coterie. Victoria, British Columbia, Canada.

### **Invited/Visiting Professor Presentations**

#### National

- 2017 Medical Decisions over the Lifespan. Edmond Safra Visiting Nurse Program, Muhammad Ali Parkinson's Center, Phoenix, AZ

#### Local/Regional

- 2020 - Present Updates on Diagnosis and Management of Lewy Body Dementia. Neurosciences Symposium/Banner University Medical Center, Phoenix, AZ, USA.
- 2020 What Pediatricians Need to Know about Tourette Syndrome, Pediatric Grand Rounds, Primary Children's Hospital, Salt Lake City , UT, USA
- 2019 Clinical and Research Updates on Tourette Syndrome. University of Utah/Tremor and Hyperkinetic Movement Disorders Conference. Salt Lake City, Utah.
- 2019 Evaluation and Management of Drug-Induced Movement Disorders. University of Utah/Tremor and Hyperkinetic Movement Disorders Conference. Salt Lake City, Utah.
- 2017 Understanding Lewy body dementia. 26th Annual Alzheimer's Association Education Conference, Scottsdale, AZ
- 2016 Talking to Clinicians about Tourette's. CDC/Tourette Association of American, Phoenix Children's Hospital, Phoenix, AZ
- 2016 What Parkinson's Research Means to You. 6th Annual Parkinson Wellness Recovery Retreat, Scottsdale, AZ

- 2016 Different from Alzheimer's: Lewy body dementia. 25th Annual Alzheimer's Association Education Conference, Scottsdale, AZ
- 2016 Progress and Hope through Parkinson Disease Research. Parkinson & Movement Disorder Alliance, Prescott, AZ
- 2015 Planning Neuroprotection Trials in Premanifest Lewy body disorders. Arizona Parkinson Disease Research Summit. Scottsdale, AZ.

**Grand Rounds Presentations**

- 2023 Essential Tremor and Atypical Parkinsonism: What's New in the Field? St Louis University, Neurology Grand Rounds, St Louis, MO
- 2018 Dreaming: A Prevention Strategy for Lewy body Disorders. Banner University Medical Center-Phoenix, Neurology Grand Rounds, Phoenix, AZ.
- 2016 Evaluation and Management of Tourette Syndrome, Psychiatry Grand Rounds, University of Arizona College of Medicine, Tucson, AZ
- 2016 Evaluation and Management of Tourette Syndrome, Pediatrics Grand Rounds, Cardon Children's Hospital, Mesa, AZ
- 2016 Clinical Updates on Tourette Syndrome, Neurology Grand Rounds, Mayo Clinic Arizona, Phoenix AZ
- 2016 Clinical updates on Tourette Syndrome, Phoenix Children's Hospital, Phoenix, AZ
- 2014 Neuroprotection Trials in Populations at-risk for Parkinson's: are we there yet? University of Utah Department of Neurology, Salt Lake City, UT

